Skip to main content
US EQUITIES OPEN CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
TY

TYRAStockTyra Biosciences Inc

Nasdaq Global Select Market · Healthcare · US

$19.78 last close 2026-11-18
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment TYRA's does — no target price to set, unlike a price alert.

Stable Ratio screen, 0 of 6 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it

Sharia status
COMPLIANT
Per our secondary compliance provider · assessed 2026-08-12
0 of 6 pass our own screen — 1 of 7 could not be computed
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 1 bearish
39
of 100
Setup confidence — system conviction, not win probabilityD

Trade plan

Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.

CANDLE · SCALP
Entry
$28.50
Stop
$27.86
Target
$29.78
Risk : Reward 2.0R

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure1 of 5 timeframes bullish · 17.4% aligned
VWAPPrice below VWAP ($19.88)
VolumeRelative volume 3.7× the 20-day average
Momentum10-day rate of change -7.8%
Overall readNEUTRAL — No Edge

Tyra Biosciences Inc (TYRA) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 434 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Wall Street consensus
BUY
22 analysts
Institutional own.
117.5% *
of shares
Momentum (10d)
-7.8%
rate of change
SMC grade
D · 39
17.4% aligned
D · 39
SMC grade — 17.4% timeframe alignment
-7.8%
Rate of change (10d)
BUY
Wall Street consensus (22)
117.5%
Institutional ownership *

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $1.5B as of 2026-11-15. At the 2026-11-18 close it is about $1.5B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 0.4% (0.4% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 31.4% (31.1% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail 1 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.37% 30.00% Pass(29.6pp buffer)
Interest-bearing investments 31.10% 30.00% Fail(1.1pp over)
Usmani Fail 2 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.75% 33.00% Pass(32.2pp buffer)
Interest-bearing investments 62.82% 33.00% Fail(29.8pp over)
Non-liquid assets 37.18% at least 20.00% Pass(17.2pp above the floor)
MSCI Fail 1 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.75% 33.33% Pass(32.6pp buffer)
Cash + interest-bearing securities 62.82% 33.33% Fail(29.5pp over)
Accounts receivable 62.82% 33.33% Fail(29.5pp over)
FTSE Fail 1 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass(33.3pp buffer)
Cash + interest-bearing securities 62.82% 33.33% Fail(29.5pp over)
Accounts receivable 62.82% 50.00% Fail(12.8pp over)
Dow Jones Islamic Market Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 3 of 3 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.36% 33.00% Pass(32.6pp buffer)
Cash + interest-bearing securities 30.52% 33.00% Pass(2.5pp buffer)
Accounts receivable 0.00% 33.00% Pass(33.0pp buffer)
S&P Shariah Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 3 of 3 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.40% 33.00% Pass(32.6pp buffer)
Cash + interest-bearing securities 33.63% 49.00% Pass(15.4pp buffer)
Accounts receivable 0.00% 49.00% Pass(49.0pp buffer)
MSCI M-Series Fail 2 of 3 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.40% 33.33% Pass(32.9pp buffer)
Cash + interest-bearing securities 33.63% 33.33% Fail(0.3pp over)
Accounts receivable 33.63% 49.00% Pass(15.4pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

MSCI Islamic M-Series (% of 36-mo avg market cap)receivables ratio 15.4pts
Usmani (% of total assets)nonliquid assets ratio · floor 17.2pts
AAOIFI Standard 21 (% of market cap)debt ratio 29.6pts
Usmani (% of total assets)investments ratio 29.8pts
MSCI Islamic Index (% of total assets)cash and interest ratio 29.5pts
MSCI Islamic Index (% of total assets)receivables ratio 29.5pts

The numbers the ratios are built from

Read from TYRA's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period not measured — —
Interest-bearing debtShort and long-term borrowings $0 2026-09-30 no debt tag reported in 3+ years (treated as $0)
Cash and interest-bearing securitiesCash, equivalents and marketable securities $457.0M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Total assetsBalance sheet total $727.5M 2026-09-30 Assets
Market capDenominator for AAOIFI $1.5B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $1.0B 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $1.1B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $12.8M 2025-12-31 InterestAndOtherIncome

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2026-09-30. Income statement as of 2025-12-31. Screened 2026-11-15.

A newer filing exists: our EDGAR watch has seen one since this screen and it is queued for re-screening. The figures below are from the filings named, not the newer one.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$727.5M
    Assets · balance sheet as of 2026-09-30
  • Interest-bearing debt$0
    no debt tag reported in 3+ years (treated as $0) · balance sheet as of 2026-09-30
  • Cash and interest-bearing securities$457.0M
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · balance sheet as of 2026-09-30
  • Receivables$0
    no receivables tag reported in 3+ years (treated as $0) · balance sheet as of 2026-09-30
  • Interest income (non-permissible)$12.8M
    InterestAndOtherIncome · income statement as of 2025-12-31
  • Market cap$1.5B
    Market-data quote at screen time, 2026-11-15 · not a filing figure, so no link

What changed, and when

Verdict history for TYRA. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-11-15 Unverified → Fail filing re-screen

Tracked since 2026-09-07.

What would change the status

The headline verdict is the majority of the decided ratio standards — 0 pass and 6 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-15.

No standard's deciding ratio sits within 3 points of its line.

The ratios that move with the share price

AAOIFI's debt ratio (0.4% against a 30% line) would only fail if the market cap fell by 99%, to $18.2M. At the 2026-11-18 close it would read 0.4%.

AAOIFI's investments ratio is $457.0M cash and interest-bearing investments over a market cap of $1.5B (as of 2026-11-15), 31.1% against a 30% line.

At the 2026-11-18 close the market cap is about $1.5B (the stored cap moved by the share price since), so this ratio would read 31.4%; the line is +5% from there. The published status changes only when the company is re-screened.

It would pass if the market cap rose above $1.5B (+4%), about $22.05 a share against $21.27 implied by the screen's own figures.

AAOIFI would then be unverified.

At the screen's market cap, it would take $16.2M less cash and interest-bearing investments to clear the line.

AAOIFI would then be unverified.

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold TYRA

7 of the 239 funds whose filed holdings we currently hold own TYRA shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns TYRA.

You may already own it

Widely held U.S. index funds. If you own one, you own TYRA through it. None of them is a Shariah fund; the last column is our look-through of each.

FundTYRA in fundFund compliant by weight
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.00% 54%
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00% 54%
SCHB Schwab U.S. Broad Market ETF 0.00% 53%
Other funds
FundTYRA in fundFund compliant by weight
LCMGX Lord Abbett Micro-Cap Growth Fund 0.78% 51%
FBDIX Franklin Biotechnology Discovery Fund 0.17% not computed
TMSL T. Rowe Price Small-Mid Cap ETF 0.08% 43%
TEIHX Nuveen Equity Index Fund 0.00% 51%

Sorted by TYRA’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names TYRA once, so a bond is not counted as the shares; 1 more fund name TYRA in a way we cannot separate from its bonds, and is not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding TYRA
InvestorFirmPositionWeightAs of
Ken Griffin Citadel Advisors $5M 0.0% 2026-09-30
Paul Tudor Jones Tudor Investment Corp $1M 0.0% 2026-09-30
Israel Englander Millennium Management $1M 0.0% 2026-09-30
Ken Fisher Fisher Asset Management $1M 0.0% 2026-09-30
David Shaw D. E. Shaw & Co. $1M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

39.6133.7227.8321.9316.042025-11-182026-05-212026-11-18

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
17.56
S2
18.45
S1
19.01
PIVOT
19.90
R1
20.46
R2
21.35
R3
21.91

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
16.79 – 25.23
±20.08% from 21.01, made 2026-10-03 · resolves 2026-10-10
STRONG SELL
from 19 indicators
77.1% of our last 20463 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 50.1% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)39.40NEUTRAL
Stochastic %K (14)4.81BUY
CCI (20)-145.66BUY
Williams %R (14)-95.19BUY
MACD (12,26,9)-0.13SELL
ROC (10)-9.69SELL
Momentum (10)-2.08SELL
EMA (10)20.23SELL
SMA (10)20.48SELL
EMA (20)20.56SELL
SMA (20)20.83SELL
EMA (30)20.88SELL
SMA (30)20.38SELL
EMA (50)21.81SELL
SMA (50)21.38SELL
EMA (100)24.03SELL
SMA (100)25.06SELL
EMA (200)26.66SELL
SMA (200)29.24SELL

About Tyra Biosciences Inc

Healthcare · Biotechnology

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

tyra.bio ↗

Background via Yahoo Finance — informational, not part of the verdict.

Latest Signal — 2026-09-04

CANDLE
Type · SCALP
28.50
Entry
27.86
Stop
29.78
Target
LOSS
Outcome · exit 27.86 (-2.25%)

Stop 27.86 Now 19.78 Target 29.78

Verdict

⚪ NEUTRAL — No Edge

Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.

Scores: 2 bullish / 1 bearish

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily RANGING 64
⏰ 4H RANGING 37
🕐 1H BULLISH 98
⏱ 15-Min RANGING 130
⏲ 5-Min RANGING 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-7.8%
Rate of change (10d)
3.7×
Volume vs its 20-day average
-0.39
MACD (no fresh cross)
$19.95
Volume POC (today)
$19.63 – $20.08
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.